Skip to main content
Log in

Paradoxical palmoplantar pustulosis induced by secukinumab and brodalumab: a report of three cases

  • Correspondence
  • Published:
European Journal of Dermatology Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Puig L. Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others. Curr Probl Dermatol 2018; 53: 49–63.

    Article  Google Scholar 

  2. Dogra S, Bishnoi A, Narang T, Handa S. Secukinumab-induced paradoxical pustular psoriasis. Clin Exp Dermatol 2019; 44: 72–3.

    Article  CAS  Google Scholar 

  3. Nakao M, Asano Y, Kamata M, Yoshizaki A, Sato S. Successful treatment of palmoplantar pustular psoriasis with brodalumab. Eur J Dermatol 2018; 28: 538–9.

    Article  Google Scholar 

  4. Takahashi H, Sato K, Takagi A, Iizuka H. Brodalumab-induced palmar pustular eruption and joint swelling accompanied by muscle pains in two cases of psoriasis. J Dermatol 2018; 45: e325–6.

    Article  Google Scholar 

  5. Wilsmann-Theis D, Jacobi A, Frambach A, et al. Palmoplantar pustulosis — a cross-sectional analysis in Germany. Dermatol Online J 2017; 23: 4.

    Google Scholar 

  6. Mössner R, Thaci D, Mohr J, et al. Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases. Arch Dermatol Res 2008; 300: 101–5.

    Article  Google Scholar 

  7. Bae JM, Lee HH, Lee BI, et al. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Aliment Pharmacol Ther 2018; 48: 196–205.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Rotraut Mössner or Andreas Pinter.

Additional information

Disclosure

Funding source: none. Conflicts of interest: RM has been an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials by the following companies: Abbott/Abbvie, Allmirall, Biogen IDEC GmbH, Böhringer-Ingelheim, Celgene, Essex Pharma GmbH, Janssen-Cilag GmbH, Leo Pharma GmbH, Lilly, Merck Serono GmbH, MSD SHARP & DOHME GmbH, Novartis Pharma GmbH, Pfizer GmbH and UCB. AP has been an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials by the following companies: AbbVie, Almirall-Hermal, Amgen, Biogen Idec, Boehringer-Ingelheim, Celgene, GSK, Eli-Lilly, Galderma, Hexal, Janssen, LEO-Pharma, MC2, Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Schering-Plough und UCB Pharma.

Supplementary material

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mössner, R., Pinter, A. Paradoxical palmoplantar pustulosis induced by secukinumab and brodalumab: a report of three cases. Eur J Dermatol 30, 177–178 (2020). https://doi.org/10.1684/ejd.2020.3702

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2020.3702

Navigation